Basil Sharrack

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

A genetic study of Wilson’s disease in the United Kingdom

Alison J. Coffey, Miranda Durkie, Stephen Hague et al. · Brain · 2013 · 353 citations · Full text

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

The effect of anti-α4 integrin antibody on brain lesion activity in MS

Niall Tubridy, P. O. Behan, Rudy Capildeo et al. · Neurology · 1999 · 308 citations

The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis

Basil Sharrack, Richard AC Hughes · Multiple Sclerosis Journal · 1999 · 289 citations